Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) was the target of some unusual options trading on Thursday. Investors bought 6,277 call options on the stock. This is an increase of 2,571% compared to the typical volume of 235 call options.

Taysha Gene Therapies Stock Down 3.1%

Shares of TSHA traded down $0.19 during midday trading on Thursday, reaching $5.82. 2,143,459 shares of the stock were exchanged, compared to its average volume of 2,748,110. Taysha Gene Therapies has a 12-month low of $1.13 and a 12-month high of $6.04. The firm has a 50 day simple moving average of $4.56 and a 200-day simple moving average of $4.74. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -17.10 and a beta of 1.10.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $1.89 million. Research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

TSHA has been the subject of several research analyst reports. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Chardan Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Canaccord Genuity Group increased their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Finally, Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.64.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sean P. Nolan sold 41,312 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the transaction, the chief executive officer directly owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This represents a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 598,623 shares of company stock valued at $2,772,188 over the last three months. Insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Marex Group plc bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at approximately $31,000. ST Germain D J Co. Inc. raised its stake in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at approximately $40,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after acquiring an additional 10,742 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.